vibegron + tolterodine

A combination of **vibegron**, a selective beta-3 adrenergic receptor agonist, and **tolterodine**, a muscarinic (anticholinergic) receptor antagonist. Vibegron works by stimulating beta-3 adrenergic receptors in the bladder detrusor muscle, promoting relaxation during the storage phase and increasing bladder capacity. Tolterodine inhibits muscarinic receptors in the bladder, reducing detrusor muscle contractions. This combination is being evaluated for the treatment of **overactive bladder (OAB)** with symptoms such as urinary frequency, urgency, and urge incontinence. The combination intends to improve efficacy by targeting both beta-adrenergic and muscarinic pathways. Clinical studies have demonstrated that vibegron is effective and well-tolerated both as monotherapy and in combination with tolterodine, with combination therapy being considered especially when monotherapy is inadequate[1][5].

Brand names

Gemtesa (vibegron)Detrol (tolterodine)

Other names

vibegron and tolterodine combination